Zyoxel to become CN Bio Innovations

HONG KONG and OXFORD, England – Zyoxel, an expert in advanced in vitro 3D liver models for drug discovery and drug testing, has today announced it is changing its name to CN Bio Innovations Ltd (CNBIO). The move is part of a strategic rebrand designed to closer align the organisation with its Hong Kong-based holding company, CN Innovations Holdings Limited (CNI).

“Since our founding in 2009, we have enjoyed a productive relationship with CNI, benefiting from their extensive and diverse business experience under the leadership of company director and CNI managing director, Charles Chong,” said Maureen Coleman, chair of CNBIO.

CNI traces its roots to 1935, when the Chung Nam Company was founded by the late Mr and Mrs Chong Ching Um in Hong Kong. Today, the CNI Group is a multi-national organisation, headquartered in Hong Kong and Southern China, with expertise spanning materials science, precision engineering and aesthetics technologies.

As part of the rebrand, Zyoxel will change its corporate website to www.cn-bio.com.

“The name change ensures that we are more effectively aligned with the brand of our holding company and clarifies our status as an integral part of the CNI family. It also reflects the increasing confidence and commitment of our principal shareholder, and signifies the start of an exciting new phase in CNBIO’s development,” Ms Coleman said.

CNBIO will continue to provide human biomimetic platforms for the testing and development of therapeutics for serious human diseases and to work closely with academic pioneers in the bio-engineering field. The company will also continue to promote and support LiverChip products and services for customers in the drug metabolism and toxicology fields.